EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease

Tuhin Virmani iD, Lakshmi Pillai, Reid D Landes, Aliyah Glover, Shannon Doerhoff, Jennifer Kleiner, Mitesh Lotia, Rohit Dhall, Edgar Garcia-Rill

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70276 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Tuhin Virmani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. Hauptthemen laut MEDLINE: Modafinil, Parkinson Disease, Gait Disorders, Neurologic, Outcome Assessment, Health Care. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Arkansas for Medical Sciences, Parkinson's Foundation, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Freezing of gait (FOG) in people with Parkinson's disease (PwPD) is debilitating and has limited treatments. Modafinil modulates beta/gamma band activity in the pedunculopontine nucleus (PPN), like PPN deep brain stimulation. We therefore tested the hypothesis that Modafinil would improve FOG in PwPD.

Methods

PwPD with FOG were randomized to early‐start (24 weeks modafinil) or delayed‐start (12 weeks each, placebo then modafinil) of oral modafinil 50 mg, followed by a 2‐week washout for both arms. Primary outcomes were change in OFF‐levodopa stride length and FOG questionnaire scores; secondary outcomes were change in motor Unified Parkinson's Disease Rating Scale (UPDRS), sleep and quality‐of‐life scores, and post hoc outcome was change in percent freezing time (%FT).

Results

Early‐ ( n = 12) and delayed‐start ( n = 9) group participants were well matched for age, OFF‐levodopa motor UPDRS and FOG‐Q scores. Primary and secondary outcomes did not reach statistical significance. Limiting the analysis to study completers with quantifiable visualized freezing at the initial visit and collapsing the two study arms ( n = 11), %FT trended to improvement with 50 mg modafinil in 8/11 participants ( p = 0.15) and worsening after 2 weeks washout in 9/11 participants ( p = 0.09). A future cross‐over study with 50 participants would have 0.80 power to detect a 0.5 standard‐deviation improvement in %FT.

Interpretation

For future therapeutic trials, selecting PwPD with moderate, quantifiable FOG and utilizing appropriate outcome measures like %FT will improve the ability to identify intervention effects. Even for short trials, analyses must account for gait decline. An FOG outcome measure that requires less analysis time burden than video quantification, and the ability for at‐home monitoring is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ModafinilParkinson DiseaseGait Disorders, NeurologicOutcome Assessment, Health CareWakefulness-Promoting AgentsHumansMaleFemaleMiddle AgedAgedDouble-Blind Method

Stichwörter der Autor:innen

Parkinson's diseaseclinical trialdelayed‐start designfreezing of gaitvideo‐based gait quantification

Substanzen

ModafinilWakefulness-Promoting Agents

Autor:innen und Institutionen

  • Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Center for Translational Neuroscience, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

ORCID-Profile: Tuhin Virmani

Förderung

  • University of Arkansas for Medical Sciences
  • Parkinson's Foundation
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Virmani, T., Pillai, L., Landes, R. D., Glover, A., Doerhoff, S., Kleiner, J., Lotia, M., Dhall, R., & Garcia-Rill, E. (2025). Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70276

Vancouver

Virmani T, Pillai L, Landes RD, Glover A, Doerhoff S, Kleiner J, et al. Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70276

BibTeX
@article{Virmani2025,
  author = {Virmani, Tuhin and Pillai, Lakshmi and Landes, Reid D and Glover, Aliyah and Doerhoff, Shannon and Kleiner, Jennifer and Lotia, Mitesh and Dhall, Rohit and Garcia-Rill, Edgar},
  title = {Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70276}
}
Kostenlos starten →